生物醫藥領域正在高速發展時期，人源化動物模型已經成為基礎科學、藥物藥效評價、藥理研究中不可或缺的工具。尊龙凯时人生就是搏官网製備的一係列人源化小鼠模型，已經成功應用於腫瘤免疫、自身免疫等基礎研究及藥物開發，頻現於各大頂級生物醫藥領域期刊，獲得國內外合作夥伴認可，現在就跟小編一起領略一下他們的風采吧!

文章錦集

4-1BB靶點動物模型

01

文章名稱

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes

發表期刊

SCIENCE ADVANCES

發表單位

Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea.

ABL Bio Inc., Seongnam, Republic of Korea.

Department of Life Sciences, POSTECH, Pohang, Republic of Korea.

使用小鼠及腫瘤模型

B-h4-1BB mice, MC38-hB7-H3 tumor

02

文章名稱

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist

發表期刊

Journal for ImmunoTherapy of Cancer

發表單位

Bicycle Therapeutics, Lexington, Massachusetts, USA

使用小鼠及腫瘤模型

B-hTNFRSF9(CD137) mice, MC38 tumor

03

文章名稱

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

發表期刊

Nature Communications

發表單位

Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.

Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, 200240 Shanghai, China.

Lyvgen Biopharma,Shanghai, China.

Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China

使用小鼠

B-h4-1BB mice

SIRPα/CD47靶點動物模型

01

文章名稱

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

發表期刊

Cancer Immunology, Immunotherapy

發表單位

Department of Clinical Pharmacology, First Affiliated Hospital of Soochow University, 899 Pinghai Road, Gusu

District, Suzhou 215006, Jiangsu Province, China;NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, 20 Qianrong Road, Binhu District, Wuxi, Jiangsu Province, China

Institute for Interdisciplinary Drug Research and Translational Sciences, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

Innovent Biologics (Suzhou) Co., Ltd., 168 Dongping Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, China

使用小鼠及腫瘤模型

B-hCD47 mice, MC38-PD-L1-CD47 cells

02

文章名稱

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody

發表期刊

mAbs

發表單位

Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou, China;

Institute for Interdisciplinary Drug Research and Translational Sciences, College of Pharmaceutical Sciences, Soochow University, Suzhou, China;

NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China;

Drug Discovery Department, Innovent Biopharmaceutical (Suzhou) Co., Ltd, Suzhou, China

使用小鼠及腫瘤模型

B-hCD47 mice, MC38 tumor (hCD47 and hPDL1)

03

文章名稱

Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy

發表期刊

JCI Insight

發表單位

Forty Seven Inc., Menlo Park, California, USA.

Division of Hematology, Department of Medicine, and 3Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.

使用小鼠模型

B-hCD47/SIRPα mice, B16F10 tumor；hSirpα B-NDG mice, Raji cell

04

文章名稱

Preclinical efficacy and toxicity studies of a highly specific chimeric anti‐CD47 antibody

發表期刊

FEBS Journal 

發表單位

School of Life Sciences, Fudan University, Shanghai, China

Biologics Discovery, Shanghai ChemPartner Co., Ltd., Shanghai, China

Biologics Discovery, Shanghai Hyamab Biotechnology Co., Ltd., Shanghai, China

使用小鼠

B-hCD47/hSIRPα mice

PD-1/PD-L1靶點相關模型

01

文章名稱

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1

發表期刊

NATURE COMMUNICATIONS

發表單位

Arbutus Biopharma Inc, Warminster, PA, USA. 

Xtal BioStructures Inc., Natick, MA, USA

使用小鼠及腫瘤模型

B-hPD-1/hPD-L1 mice, MC38-hPD-L1 tumor

02

文章名稱

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade

發表期刊

Biochemical and Biophysical Research Communications

發表單位

Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China

Shanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai, China

使用小鼠

B-hPD-L1 mice

FcRn人源化小鼠模型

01

文章名稱

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

發表期刊

Cancer Immunology, Immunotherapy

發表單位

School of Pharmacy, Shanghai JiaoTong University

使用小鼠

B-hFcRn mice

02

文章名稱

An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases

發表期刊

Frontiers in Immunology

發表單位

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University

School of Pharmacy, Shanghai, China, 2 Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, China

使用小鼠

B-hFcRn mice

03

文章名稱

Oral uptake and persistence of the FnAb-8 protein characterized by in situ radio-labeling and PET/CT imaging

發表期刊

Asian Journal of Pharmaceutical Sciences

發表單位

School of Pharmacy and Chemistry, DaLi University, Dali, China

School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China

使用小鼠

B-hFcRn mice

IL-4相關靶點人源化小鼠模型

01

文章名稱

The establishment of humanized IL-4/IL-4RA mouse model by gene editing and efficacy evaluation

發表期刊

Immunobiology

發表單位

College of Life Science and Technology, Beijing University of Chemical Technology

使用小鼠

B-hIL-4/hIL-4RA mice

想驗證藥物有效性及安全性，獲取優質數據，了解更多人源化動物模型趕快點擊“尊龙凯时人生就是搏官网”，獲取小鼠目錄，找到藥物研發的助推利器吧。